Shionogi & Co Ltd

It is now time to begin.

Good afternoon. Kyokawa from the Public Relations of Shionogi Pharmaceuticals. Thank you very much for joining us today. From now, we would like to begin the presentation of the final results of the first quarter of fiscal 2022 of Shionogi and Company Limited. First, let me introduce the people on the stage. John Keller, PhD, Senior Executive Officer, Senior Vice President of R&D Supervisory Unit, Toshinobu Iwasaki, Ph.D., of Senior Executive Officer, Senior Vice President, Healthcare Business Supervisory Unit, and Pharmaceutical Commercial Division. Next, Ruiji Kiyama, Senior Executive Officer, Senior Vice President, Corporate Strategy Division, and Corporate Planning Department. Takeki Uehara, DVM, PhD, Corporate Officer, Senior Vice President, Drug Development and Regulatory Science Division, and Susumu Mitsumori, a PhD, Vice President, Finance and Accounting Department. President Teshirogi is in the separate room since this is the financial results of the first quarter. When necessary, we will call upon him. And the presentation will be made by Mr. Mitsumori. And then after that, Kiyama will follow up on the explanation. After that, we will have Q&A session. We plan to conclude at 4, sorry, 3.45. Today's presentation will provide it with simultaneous interpretation. Please click on the globe at the bottom of the Zoom screen and select either Japanese or English for the translation. Please refer to the instruction manual that has been provided to you beforehand. Now, let us begin. Mitsumori-san, please.

This is the overview of the first quarter of fiscal 2022 financial results. Kiyama is going to explain the activities in the following quarters.